產(chǎn)品詳情
簡單介紹：
Anti-ADAM18抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-ADAM18抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-ADAM18
Cat. Number:
Anti-ADAM18抗體KL-5849R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
ADAM18 was first described as tMDC III (testis-specific Metalloproteinase-like disintergin-like cysteine-rich Anti-ADAM18抗體protein-III). ADAM18 is a member of the ADAMs family (A Disintegrin And Metalloproteinase), but does not contain the canonical HExxHxxxxH zinc-binding metalloproteinase catalytic site. The domain structure of the fill-length ADAM18 includes a signal sequence, propeptide domain, metalloproteinase-like domain, disintegrin-like domain, cys-rich domain, EGF-like domain, a short spacer region, then the transmembrane domain and a cytoplasmic domain. Like many of the reproductive-specific ADAMS, ADAM18 plays a nonenzymatic role, or (as is the case for ADAMs 1 & 2 (fertilin alpha and beta)), the protein acts in concert with a proteolytically active ADAM to process proteins. Little is known about interactions between ADAM18 and other ADAMs. To date, 4 different sequences for human ADAM18 are published; 739, 715, 182 and 153 amino acids in length.
Also known as:
A disintegrin Anti-ADAM18抗體and metalloproteinase domain 18; ADAM 18; ADA18_HUMAN; ADAM 27; ADAM metallopeptidase domain 18; ADAM27; MGC41836; MGC88272; TMDC3; tMDCIII; Transmembrane metalloproteinase like, disintegrin like, and cysteine rich protein III.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Dog, .
●
Immunogen: KLH conjugated synthetic peptide derived from human ADAM18.
●
Predicted Molecular Weight: 62kDa.
Storage:
Shipped at 4℃, Anti-ADAM18抗體Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working Anti-ADAM18抗體dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working Anti-ADAM18抗體dilutions must be determined by the end user.
kl603Mu01 載脂蛋白B100(APOB100)多克隆抗體 Polyclonal Antibody to Apolipoprotein B100 (APOB100)
kl003Hu01 載脂蛋白B(APOB)多克隆抗體 Polyclonal Antibody to Apolipoprotein B (APOB)
kl003Mu01 載脂蛋白B(APOB)多克隆抗體 Polyclonal Antibody to Apolipoprotein B (APOB)
kl003Ra01 載脂蛋白B(APOB)多克隆抗體 Polyclonal Antibody to Apolipoprotein B (APOB)
kl704Hu01 載脂蛋白E(APOE)多克隆抗體 Polyclonal Antibody to Apolipoprotein E (APOE)
kl704Mu01 載脂蛋白E(APOE)多克隆抗體 Polyclonal Antibody to Apolipoprotein E (APOE)
kl704Ra01 載脂蛋白E(APOE)多克隆抗體 Polyclonal Antibody to Apolipoprotein E (APOE)
kl519Hu01 載脂蛋白A1(APOA1)多克隆抗體 Polyclonal Antibody to Apolipoprotein A1 (APOA1)
kl519Mu01 載脂蛋白A1(APOA1)多克隆抗體 Polyclonal Antibody to Apolipoprotein A1 (APOA1)
kl519Ra01 載脂蛋白A1(APOA1)多克隆抗體 Polyclonal Antibody to Apolipoprotein A1 (APOA1)
kl033Hu01 干擾素α(IFNα)多克隆抗體 Polyclonal Antibody to Interferon Alpha (IFNa)
kl033Ra01 干擾素α(IFNα)多克隆抗體 Polyclonal Antibody to Interferon Alpha (IFNa)
kl578Hu01 Pim-1原癌基因(PIM1)多克隆抗體 Polyclonal Antibody to Pim-1 Oncogene (PIM1)
kl578Mu01 Pim-1原癌基因(PIM1)多克隆抗體 Polyclonal Antibody to Pim-1 Oncogene (PIM1)
kl578Ra01 Pim-1原癌基因(PIM1)多克隆抗體 Polyclonal Antibody to Pim-1 Oncogene (PIM1)
kl305Hu01 甲狀腺結(jié)合球蛋白(TBG)多克隆抗體 Polyclonal Antibody to Thyroxine Binding Globulin (TBG)
kl305Mu01 甲狀腺結(jié)合球蛋白(TBG)多克隆抗體 Polyclonal Antibody to Thyroxine Binding Globulin (TBG)
kl305Ra01 甲狀腺結(jié)合球蛋白(TBG)多克隆抗體 Polyclonal Antibody to Thyroxine Binding Globulin (TBG)
kl702Hu01 硫氧化還原蛋白(Trx)多克隆抗體 Polyclonal Antibody to Thioredoxin (Trx)
kl702Mu01 硫氧化還原蛋白(Trx)多克隆抗體 Polyclonal Antibody to Thioredoxin (Trx)
kl702Ra01 硫氧化還原蛋白(Trx)多克隆抗體 Polyclonal Antibody to Thioredoxin (Trx)
kl084Mu01 瘦素(LEP)多克隆抗體 Polyclonal Antibody to Leptin (LEP)
kl084Ra01 瘦素(LEP)多克隆抗體 Polyclonal Antibody to Leptin (LEP)
